Index RUT
P/E -
EPS (ttm) -1.13
Insider Own 48.58%
Shs Outstand 102.20M
Perf Week -5.26%
Market Cap 789.62M
Forward P/E -
EPS next Y -1.52
Insider Trans -0.76%
Shs Float 54.94M
Perf Month -4.89%
Income -111.65M
PEG -
EPS next Q -0.35
Inst Own 56.62%
Short Float 19.82%
Perf Quarter -35.79%
Sales 37.23M
P/S 21.21
EPS this Y -34.05%
Inst Trans -2.66%
Short Ratio 18.71
Perf Half Y -2.89%
Book/sh 2.48
P/B 2.98
EPS next Y -5.30%
ROA -27.57%
Short Interest 10.89M
Perf Year 89.00%
Cash/sh 3.22
P/C 2.30
EPS next 5Y -
ROE -45.41%
52W Range 2.47 - 13.03
Perf YTD -25.35%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -37.14%
52W High -43.28%
Beta 0.80
Dividend TTM -
Quick Ratio 8.23
Sales past 5Y 132.62%
Gross Margin 90.97%
52W Low 199.19%
ATR (14) 0.42
Dividend Ex-Date -
Current Ratio 8.23
EPS Y/Y TTM 10.35%
Oper. Margin -338.80%
RSI (14) 44.35
Volatility 3.82% 5.63%
Employees 140
Debt/Eq 0.14
Sales Y/Y TTM 49.72%
Profit Margin -299.88%
Recom 1.12
Target Price 17.57
Option/Short Yes / Yes
LT Debt/Eq 0.14
EPS Q/Q -10.36%
Payout -
Rel Volume 0.64
Prev Close 7.47
Sales Surprise -13.76%
EPS Surprise -12.90%
Sales Q/Q 12.23%
Earnings May 08 BMO
Avg Volume 582.07K
Price 7.39
SMA20 -2.93%
SMA50 -4.94%
SMA200 -17.24%
Trades
Volume 374,795
Change -1.07%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-04-24 Initiated
Cantor Fitzgerald
Overweight
Feb-12-24 Initiated
Piper Sandler
Overweight
$18
Dec-08-23 Initiated
B. Riley Securities
Buy
$16
Oct-20-22 Upgrade
H.C. Wainwright
Neutral → Buy
$10
Sep-20-21 Initiated
SVB Leerink
Outperform
$25
May-08-24 01:53PM
08:10AM
07:00AM
May-07-24 10:00AM
Apr-01-24 04:48PM
05:31AM
Loading…
Mar-20-24 05:31AM
Mar-18-24 02:52PM
08:10AM
07:00AM
Mar-17-24 05:20PM
Mar-06-24 07:00AM
Mar-05-24 04:47PM
Feb-07-24 08:55AM
Jan-31-24 07:00AM
Jan-05-24 04:05PM
02:47AM
Loading…
Jan-04-24 02:47AM
Jan-03-24 07:00AM
Nov-13-23 07:00AM
Nov-08-23 03:12PM
07:00AM
Nov-07-23 07:00AM
Oct-10-23 11:28AM
Oct-09-23 08:50AM
Sep-18-23 07:00AM
Sep-06-23 07:00AM
Sep-05-23 07:00AM
Aug-29-23 05:08PM
Aug-28-23 07:00AM
Aug-10-23 07:00AM
Aug-07-23 07:00AM
07:00AM
Loading…
Jul-24-23 07:00AM
Jul-10-23 07:00AM
Jun-01-23 07:00AM
May-09-23 07:00AM
Apr-18-23 04:30PM
Apr-03-23 07:00AM
Mar-27-23 07:00AM
Mar-14-23 08:11PM
Mar-10-23 10:15PM
Mar-06-23 07:00AM
Mar-01-23 07:00AM
Feb-28-23 07:00AM
Feb-02-23 07:00AM
Jan-25-23 07:00AM
Dec-15-22 07:00AM
Nov-10-22 07:00AM
Nov-07-22 07:00AM
Oct-19-22 07:00AM
Oct-05-22 08:10AM
Sep-06-22 07:00AM
Aug-13-22 08:27AM
Aug-10-22 07:00AM
Aug-02-22 07:00AM
Jun-27-22 07:00AM
Jun-20-22 07:26AM
Jun-08-22 07:00AM
May-11-22 07:00AM
May-09-22 07:00AM
Apr-19-22 07:22AM
Mar-28-22 07:00AM
Mar-08-22 04:57PM
Mar-03-22 09:41AM
Feb-28-22 07:00AM
Feb-02-22 07:00AM
Jan-24-22 07:00AM
Jan-11-22 09:37AM
Dec-21-21 06:38PM
Nov-11-21 07:00AM
Nov-10-21 10:42AM
Nov-09-21 07:00AM
Nov-01-21 07:00AM
Sep-30-21 04:31PM
Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
MVA Investors, LLC May 03 '24 Sale 7.61 60,000 456,600 483,524 May 03 09:34 PM MVA Investors, LLC May 02 '24 Sale 7.56 75,000 567,000 543,524 May 03 09:34 PM MVA Investors, LLC May 01 '24 Sale 7.43 75,000 557,250 618,524 May 03 09:34 PM Third Rock Ventures IV, L.P. 10% Owner Feb 20 '24 Sale 12.00 162,500 1,950,000 19,201,475 Feb 21 05:52 PM Weber Barbara Chief Executive Officer Feb 07 '24 Sale 12.62 4,457 56,246 1,535,167 Feb 08 09:14 PM Crystal Adam See Remarks Feb 07 '24 Sale 12.62 4,083 51,527 119,478 Feb 08 09:04 PM Beckman Daniella Chief Financial Officer Feb 07 '24 Sale 12.62 1,817 22,930 132,397 Feb 08 09:08 PM Barry Douglas General Counsel Feb 07 '24 Sale 12.62 1,354 17,087 43,981 Feb 08 09:09 PM Weber Barbara Chief Executive Officer Feb 06 '24 Sale 12.56 4,681 58,806 1,539,624 Feb 08 09:14 PM Crystal Adam See Remarks Feb 06 '24 Sale 12.56 4,288 53,868 123,561 Feb 08 09:04 PM Beckman Daniella Chief Financial Officer Feb 06 '24 Sale 12.56 1,908 23,969 134,214 Feb 08 09:08 PM Barry Douglas General Counsel Feb 06 '24 Sale 12.56 1,422 17,864 45,335 Feb 08 09:09 PM Crystal Adam See Remarks Nov 01 '23 Sale 8.39 7,507 62,994 81,250 Nov 02 04:49 PM Boxer Capital, LLC Oct 16 '23 Buy 6.84 500,000 3,420,000 8,198,642 Oct 17 06:04 PM Boxer Capital, LLC Oct 13 '23 Buy 7.07 750,000 5,302,500 7,698,642 Oct 17 06:04 PM Boxer Capital, LLC Oct 09 '23 Sale 9.97 175,000 1,744,750 6,948,642 Oct 11 09:22 PM Boxer Capital, LLC Oct 09 '23 Sale 9.91 50,000 495,500 693,524 Oct 11 09:22 PM Boxer Capital, LLC Aug 11 '23 Buy 5.15 475,000 2,446,250 743,542 Aug 15 09:34 PM
Index RUT
P/E -
EPS (ttm) -1.68
Insider Own 49.20%
Shs Outstand 43.02M
Perf Week -4.07%
Market Cap 928.19M
Forward P/E -
EPS next Y -2.09
Insider Trans -0.85%
Shs Float 26.66M
Perf Month 8.00%
Income -75.45M
PEG -
EPS next Q -0.41
Inst Own 52.26%
Short Float 12.90%
Perf Quarter -6.25%
Sales 0.00M
P/S -
EPS this Y -5.66%
Inst Trans -0.09%
Short Ratio 25.92
Perf Half Y 56.97%
Book/sh 7.43
P/B 2.38
EPS next Y -22.20%
ROA -22.87%
Short Interest 3.44M
Perf Year 22.08%
Cash/sh 7.29
P/C 2.43
EPS next 5Y -
ROE -23.63%
52W Range 10.38 - 20.67
Perf YTD 27.73%
Dividend Est. -
P/FCF -
EPS past 5Y -102.86%
ROI -19.05%
52W High -14.42%
Beta 1.08
Dividend TTM -
Quick Ratio 44.83
Sales past 5Y 0.00%
Gross Margin -
52W Low 70.42%
ATR (14) 1.17
Dividend Ex-Date -
Current Ratio 44.83
EPS Y/Y TTM -35.33%
Oper. Margin 0.00%
RSI (14) 50.45
Volatility 6.50% 6.97%
Employees 49
Debt/Eq 0.02
Sales Y/Y TTM -
Profit Margin -
Recom 1.33
Target Price 25.20
Option/Short Yes / Yes
LT Debt/Eq 0.02
EPS Q/Q -24.30%
Payout -
Rel Volume 0.52
Prev Close 18.45
Sales Surprise -
EPS Surprise 23.08%
Sales Q/Q -
Earnings May 09 AMC
Avg Volume 132.75K
Price 17.69
SMA20 -0.19%
SMA50 4.31%
SMA200 17.31%
Trades
Volume 69,142
Change -4.12%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-15-23 Downgrade
BofA Securities
Buy → Neutral
$25 → $15
Jun-30-23 Initiated
Wedbush
Outperform
$27
Feb-03-23 Initiated
Oppenheimer
Outperform
$17
Jun-23-22 Initiated
H.C. Wainwright
Buy
$12
Mar-08-22 Upgrade
Jefferies
Hold → Buy
$31 → $27
Nov-08-21 Downgrade
Jefferies
Buy → Hold
Oct-11-21 Initiated
Jefferies
Buy
$19
Oct-11-21 Initiated
Cowen
Outperform
Oct-11-21 Initiated
BofA Securities
Buy
$22
May-09-24 10:54PM
04:05PM
May-07-24 04:05PM
Mar-19-24 09:53PM
09:01PM
04:05PM
Loading…
04:05PM
Mar-05-24 11:27PM
Mar-01-24 12:40AM
Feb-27-24 04:05PM
Feb-07-24 04:05PM
03:12AM
Feb-02-24 08:00AM
Feb-01-24 05:30PM
Dec-29-23 06:45AM
Dec-22-23 09:00AM
04:05PM
Loading…
Nov-08-23 04:05PM
Nov-07-23 04:05PM
Sep-21-23 08:00AM
Sep-12-23 04:05PM
Aug-10-23 04:05PM
Aug-01-23 08:00AM
Jun-16-23 08:50AM
Jun-07-23 09:55AM
May-25-23 08:00AM
May-23-23 08:50AM
May-22-23 09:55AM
Apr-09-23 09:30AM
Mar-29-23 04:05PM
Mar-27-23 08:50AM
Mar-22-23 04:05PM
08:40AM
Loading…
Mar-01-23 08:40AM
07:00AM
Feb-22-23 04:05PM
Nov-29-22 07:00AM
Nov-24-22 09:55AM
Nov-10-22 04:20PM
Nov-08-22 09:55AM
Nov-03-22 04:05PM
Nov-02-22 04:05PM
Oct-31-22 09:22AM
Oct-13-22 08:00AM
Sep-08-22 04:05PM
Sep-05-22 08:15AM
Aug-04-22 04:05PM
May-24-22 08:55AM
May-05-22 04:05PM
Mar-03-22 04:05PM
Feb-22-22 04:05PM
Dec-21-21 06:38PM
Dec-15-21 09:29AM
Nov-10-21 04:05PM
Nov-03-21 04:05PM
Sep-22-21 08:22AM
Sep-20-21 07:52AM
Sep-17-21 05:28AM
Sep-15-21 10:41AM
Sep-14-21 09:00PM
06:51AM
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SNAP, enables the rapid and precise refinement of structural design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Bensen Daniel Chief Operating Officer Mar 11 '24 Sale 20.00 200 4,000 431,683 Mar 13 05:46 PM Bensen Daniel Chief Operating Officer Mar 07 '24 Sale 20.00 68 1,360 431,883 Mar 08 05:38 PM Bensen Daniel Chief Operating Officer Mar 06 '24 Sale 20.09 1,733 34,819 431,951 Mar 08 05:38 PM Bensen Daniel Chief Operating Officer Mar 05 '24 Sale 20.02 1,189 23,802 433,684 Mar 05 05:40 PM Bensen Daniel Chief Operating Officer Mar 04 '24 Sale 20.08 5,063 101,654 434,873 Mar 05 05:40 PM Bensen Daniel Chief Operating Officer Mar 01 '24 Sale 20.04 2,900 58,112 439,936 Mar 05 05:40 PM Bensen Daniel Chief Operating Officer Feb 29 '24 Sale 20.00 2,050 41,003 442,836 Feb 29 06:58 PM Bensen Daniel Chief Operating Officer Feb 28 '24 Sale 20.13 5,849 117,729 444,886 Feb 29 06:58 PM Bensen Daniel Chief Operating Officer Feb 27 '24 Sale 20.00 745 14,900 450,735 Feb 29 06:58 PM Bensen Daniel Chief Operating Officer Feb 12 '24 Sale 20.00 1,501 30,020 451,480 Feb 14 09:00 PM Bensen Daniel Chief Operating Officer Feb 07 '24 Sale 18.09 9,587 173,466 452,981 Feb 09 07:26 PM Bensen Daniel Chief Operating Officer Feb 06 '24 Sale 18.09 15,413 278,827 462,568 Feb 06 08:23 PM Harris Todd President and CEO Feb 05 '24 Sale 16.97 13,817 234,430 1,502,697 Feb 06 08:22 PM Bensen Daniel Chief Operating Officer Feb 02 '24 Option Exercise 0.61 25,393 15,490 553,374 Feb 06 08:23 PM Harris Todd President and CEO Feb 02 '24 Sale 16.50 86,183 1,421,655 1,516,514 Feb 06 08:22 PM Bensen Daniel Chief Operating Officer Feb 02 '24 Sale 16.33 75,393 1,231,097 477,981 Feb 06 08:23 PM Bensen Daniel Chief Operating Officer Jul 21 '23 Option Exercise 0.61 3,900 2,379 531,881 Jul 21 08:52 PM Bensen Daniel Chief Operating Officer Jul 21 '23 Sale 16.01 3,900 62,428 527,981 Jul 21 08:52 PM Bensen Daniel Chief Operating Officer Jul 19 '23 Option Exercise 0.61 207 126 528,188 Jul 21 08:52 PM Bensen Daniel Chief Operating Officer Jul 19 '23 Sale 16.07 207 3,328 527,981 Jul 21 08:52 PM Bensen Daniel Chief Operating Officer Jul 17 '23 Option Exercise 0.61 1,900 1,159 529,881 Jul 17 07:35 PM Bensen Daniel Chief Operating Officer Jul 17 '23 Sale 16.03 1,900 30,464 527,981 Jul 17 07:35 PM Bensen Daniel Chief Operating Officer Jul 13 '23 Option Exercise 0.61 500 305 528,481 Jul 17 07:35 PM Bensen Daniel Chief Operating Officer Jul 13 '23 Sale 16.13 500 8,065 527,981 Jul 17 07:35 PM Bensen Daniel Chief Operating Officer Jul 12 '23 Option Exercise 0.61 201 123 528,182 Jul 12 06:41 PM Bensen Daniel Chief Operating Officer Jul 12 '23 Sale 16.23 201 3,262 527,981 Jul 12 06:41 PM Bensen Daniel Chief Operating Officer Jul 11 '23 Option Exercise 0.61 500 305 528,481 Jul 12 06:41 PM Bensen Daniel Chief Operating Officer Jul 11 '23 Sale 16.02 500 8,009 527,981 Jul 12 06:41 PM Bensen Daniel Chief Operating Officer Jul 10 '23 Option Exercise 0.61 1,202 733 529,183 Jul 12 06:41 PM Bensen Daniel Chief Operating Officer Jul 10 '23 Sale 16.01 1,202 19,240 527,981 Jul 12 06:41 PM Bensen Daniel Chief Operating Officer Jul 03 '23 Option Exercise 0.61 4,265 2,602 532,246 Jul 03 05:31 PM Bensen Daniel Chief Operating Officer Jul 03 '23 Sale 16.37 4,265 69,814 527,981 Jul 03 05:31 PM Bensen Daniel Chief Operating Officer Jun 30 '23 Option Exercise 0.61 18,819 11,480 546,800 Jul 03 05:31 PM Bensen Daniel Chief Operating Officer Jun 30 '23 Sale 16.97 18,819 319,419 527,981 Jul 03 05:31 PM Bensen Daniel Chief Operating Officer Jun 29 '23 Option Exercise 0.61 17,281 10,541 545,262 Jul 03 05:31 PM Bensen Daniel Chief Operating Officer Jun 29 '23 Sale 16.49 17,281 285,014 527,981 Jul 03 05:31 PM Bensen Daniel Chief Operating Officer Jun 28 '23 Option Exercise 0.61 13,524 8,250 541,505 Jun 28 08:31 PM Bensen Daniel Chief Operating Officer Jun 28 '23 Sale 16.91 13,524 228,637 527,981 Jun 28 08:31 PM Bensen Daniel Chief Operating Officer Jun 27 '23 Option Exercise 0.61 16,028 9,777 544,009 Jun 28 08:31 PM Bensen Daniel Chief Operating Officer Jun 27 '23 Sale 16.91 16,028 271,075 527,981 Jun 28 08:31 PM Bensen Daniel Chief Operating Officer Jun 26 '23 Option Exercise 0.61 17,232 10,512 545,213 Jun 28 08:31 PM Bensen Daniel Chief Operating Officer Jun 26 '23 Sale 16.77 17,232 288,925 527,981 Jun 28 08:31 PM Harris Todd Chief Executive Officer Jun 23 '23 Sale 17.01 20,712 352,261 1,601,276 Jun 26 07:30 PM Harris Todd Chief Executive Officer Jun 22 '23 Sale 17.04 3,478 59,251 1,621,988 Jun 26 07:30 PM Harris Todd Chief Executive Officer Jun 21 '23 Sale 17.36 19,756 342,972 1,625,466 Jun 21 08:16 PM Harris Todd Chief Executive Officer Jun 20 '23 Sale 16.53 1,300 21,493 1,645,222 Jun 21 08:16 PM Harris Todd Chief Executive Officer Jun 16 '23 Sale 17.04 54,754 933,077 1,646,522 Jun 21 08:16 PM Harris Todd Chief Executive Officer Jun 15 '23 Option Exercise 2.25 12,773 28,739 1,714,049 Jun 15 09:00 PM Bensen Daniel Chief Operating Officer Jun 15 '23 Option Exercise 0.61 12,592 7,681 540,573 Jun 15 08:58 PM Harris Todd Chief Executive Officer Jun 15 '23 Sale 16.13 12,773 205,997 1,701,276 Jun 15 09:00 PM Bensen Daniel Chief Operating Officer Jun 15 '23 Sale 16.15 12,592 203,302 527,981 Jun 15 08:58 PM Bensen Daniel Chief Operating Officer Jun 14 '23 Option Exercise 0.61 120 73 528,101 Jun 15 08:58 PM Bensen Daniel Chief Operating Officer Jun 14 '23 Sale 16.45 120 1,974 527,981 Jun 15 08:58 PM Harris Todd Chief Executive Officer Jun 13 '23 Option Exercise 2.25 7,927 17,836 1,709,203 Jun 15 09:00 PM Bensen Daniel Chief Operating Officer Jun 13 '23 Option Exercise 0.61 5,628 3,433 533,609 Jun 15 08:58 PM Harris Todd Chief Executive Officer Jun 13 '23 Sale 16.00 7,927 126,870 1,701,276 Jun 15 09:00 PM Bensen Daniel Chief Operating Officer Jun 13 '23 Sale 16.01 5,628 90,129 527,981 Jun 15 08:58 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite